1 – 10 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Late-Onset Asthma Phenotypes by Onset Age : A Cluster Analysis in Swedish Population-Based Cohorts
- Contribution to journal › Letter
- 2024
-
Mark
Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma
- Contribution to journal › Article
-
Mark
EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care
- Contribution to journal › Article
-
Mark
Metabolic pathways in immune senescence and inflammaging : Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology
- Contribution to journal › Article
- 2023
-
Mark
Efficacy of FP-025 : A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma
- Contribution to journal › Letter
-
Mark
Eosinophils—from cradle to grave
- Contribution to journal › Article
-
Mark
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
- Contribution to journal › Article
-
Mark
Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden
- Contribution to journal › Letter
-
Mark
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma : An EAACI position paper
- Contribution to journal › Article
- 2022
-
Mark
Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses : EAACI task force on eicosanoids consensus report in times of COVID-19
- Contribution to journal › Article
